Literature DB >> 19656983

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

M A Pfaller1, S A Messer, R J Hollis, L Boyken, S Tendolkar, J Kroeger, D J Diekema.   

Abstract

We examined the susceptibilities to fluconazole of 642 bloodstream infection (BSI) isolates of Candida glabrata and grouped the isolates by patient age and geographic location within the United States. Susceptibility of C. glabrata to fluconazole was lowest in the northeast region (46%) and was highest in the west (76%). The frequencies of isolation and of fluconazole resistance among C. glabrata BSI isolates were higher in the present study (years 2001 to 2007) than in a previous study conducted from 1992 to 2001. Whereas the frequency of C. glabrata increased with patient age, the rate of fluconazole resistance declined. The oldest age group (> or = 80 years) had the highest proportion of BSI isolates that were C. glabrata (32%) and the lowest rate of fluconazole resistance (5%).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656983      PMCID: PMC2756923          DOI: 10.1128/JCM.00946-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  88 in total

1.  Invasive Candida species infection: the importance of adequate empirical antifungal therapy.

Authors:  Darius Armstrong-James
Journal:  J Antimicrob Chemother       Date:  2007-07-23       Impact factor: 5.790

2.  The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis.

Authors:  James Riddell; Carol A Kauffman
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

Review 3.  Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.

Authors:  C Lichtenstern; T H Nguyen; P Schemmer; T Hoppe-Tichy; M A Weigand
Journal:  Mycoses       Date:  2008       Impact factor: 4.377

4.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.

Authors:  Michael D Parkins; Deana M Sabuda; Sameer Elsayed; Kevin B Laupland
Journal:  J Antimicrob Chemother       Date:  2007-06-18       Impact factor: 5.790

5.  Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility.

Authors:  M C Arendrup; K Fuursted; B Gahrn-Hansen; H C Schønheyder; J D Knudsen; I M Jensen; B Bruun; J J Christensen; H K Johansen
Journal:  Clin Microbiol Infect       Date:  2008-02-22       Impact factor: 8.067

6.  Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.

Authors:  Michael J Klevay; Erika J Ernst; Jesse L Hollanbaugh; Joshua G Miller; Michael A Pfaller; Daniel J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2007-11-19       Impact factor: 2.803

7.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

8.  Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.

Authors:  Jennifer K Chow; Yoav Golan; Robin Ruthazer; Adolf W Karchmer; Yehuda Carmeli; Deborah Lichtenberg; Varun Chawla; Janet Young; Susan Hadley
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

9.  Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome.

Authors:  Marie-Elisabeth Bougnoux; Guillaume Kac; Philippe Aegerter; Christophe d'Enfert; Jean-Yves Fagon
Journal:  Intensive Care Med       Date:  2007-10-02       Impact factor: 17.440

10.  Candida glabrata fungaemia in intensive care units.

Authors:  S-Y Ruan; L-N Lee; J-S Jerng; C-J Yu; P-R Hsueh
Journal:  Clin Microbiol Infect       Date:  2007-11-28       Impact factor: 8.067

View more
  46 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Invasive Candida Infections in a Pediatric Intensive Care Unit in Turkey: Evaluation of an 11-Year Period.

Authors:  Nagehan Aslan; Dincer Yildizdas; Derya Alabaz; Ozden Ozgur Horoz; Ahmet Yontem; Emine Kocabas
Journal:  J Pediatr Intensive Care       Date:  2019-09-06

3.  Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study.

Authors:  Xiaojiong Jia; Congya Li; Ju Cao; Xianan Wu; Liping Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-20       Impact factor: 3.267

4.  Michael A. Pfaller, M.D.

Authors:  Stephen A Moser
Journal:  J Clin Microbiol       Date:  2012-12-12       Impact factor: 5.948

5.  Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006.

Authors:  Shawn R Lockhart; Debra Wagner; Naureen Iqbal; Peter G Pappas; David R Andes; Carol A Kauffman; Lisa M Brumble; Susan Hadley; Randall Walker; James I Ito; John W Baddley; Tom Chiller; Benjamin J Park
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

Review 6.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

Review 7.  What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.

Authors:  Cristóbal León; Luis Ostrosky-Zeichner; Mindy Schuster
Journal:  Intensive Care Med       Date:  2014-04-10       Impact factor: 17.440

8.  The EPA2 adhesin encoding gene is responsive to oxidative stress in the opportunistic fungal pathogen Candida glabrata.

Authors:  Jacqueline Juárez-Cepeda; Emmanuel Orta-Zavalza; Israel Cañas-Villamar; Jorge Arreola-Gómez; Gloria Patricia Pérez-Cornejo; Carmen Yudith Hernández-Carballo; Guadalupe Gutiérrez-Escobedo; Irene Castaño; Alejandro De Las Peñas
Journal:  Curr Genet       Date:  2015-01-14       Impact factor: 3.886

9.  Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-year (2010 to 2012) surveillance study.

Authors:  Wei Li; Yu-An Hu; Fang-Qiu Li; Li-Ning Shi; Hai-Feng Shao; Mei Huang; Ying Wang; Dan-Dan Han; Hong Liao; Chun-Fang Ma; Guo-Yong Zhang
Journal:  Mycopathologia       Date:  2015-01-15       Impact factor: 2.574

10.  Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.

Authors:  Cau D Pham; Carol B Bolden; Randall J Kuykendall; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2013-12-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.